医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

国庆日休市 09-30 16:00:00

905.494

+25.119

+2.85%

最高908.574	最低872.902	成交量7,896万
今开880.375	昨收880.375	日振幅4.05%
总市值0.00	流通市值0.00	总股本0.00
成交额7.38亿	换手率--	流通股本0.00
市净率1.155993	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":905.49414,"timestamp":1790755705764,"preClose":880.3748,"halted":0,"volume":78960127,"delay":0,"changeRate":0.028533,"floatShares":0,"shares":0,"eps":0,"marketStatus":"国庆日休市","change":25.119324,"latestTime":"09-30 16:00:00","open":880.3748,"high":908.5735,"low":872.90247,"amount":738154347,"amplitude":0.040518,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"pbRate":1.155993,"peRate":10.56281,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2671889817","title":"复星医药（600196）披露高级管理人员辞任公告，9月30日股价上涨2.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671889817","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671889817?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:15","pubTimestamp":1790777726,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，复星医药报收于24.02元，较前一交易日上涨2.69%，最新总市值为641.44亿元。近日，复星医药发布《关于高级管理人员辞任的公告》。公告显示，2026年9月30日，上海复星医药（集团）股份有限公司董事会收到Wenjie Zhang先生的书面辞职函。因个人原因，Wenjie Zhang先生辞去公司联席总裁职务，辞任自送达董事会时生效。其原定任期至2028年6月23日。Wenjie Zhang先生不再担任上市公司及其控股子公司任何职务，且不存在未履行完毕的公开承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000037960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK1593","02196","BK0060","BK0196","BK0028","BK0096","600196","BK0239","BK0183","BK0188","BK1191","BK0012","BK0175","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205976","title":"时代天使(06699)根据首次公开发售后受限制股份单位计划发行65.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205976","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671205976?lang=zh_cn&edition=full","pubTime":"2026-09-30 18:44","pubTimestamp":1790765078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，时代天使(06699)发布公告，于2026年9月30日根据首次公开发售后受限制股份单位计划配发及发行65.8万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06699","BK1587","BK1593","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671203940","title":"完美医疗(01830.HK)：季志雄辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2671203940","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671203940?lang=zh_cn&edition=full","pubTime":"2026-09-30 18:17","pubTimestamp":1790763422,"startTime":"0","endTime":"0","summary":"格隆汇9月30日丨完美医疗(01830.HK)宣布，季志雄已辞任独立非执行董事、公司薪酬委员会主席以及公司审核委员会及提名委员会各自之成员，自2026年9月30日起生效，原因为彼希望投放更多时间于其他业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260930/32385733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1593","BK1215","01830"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671720878","title":"完美医疗(01830)：戚世昌获委任为薪酬委员会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2671720878","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671720878?lang=zh_cn&edition=full","pubTime":"2026-09-30 18:05","pubTimestamp":1790762727,"startTime":"0","endTime":"0","summary":"智通财经APP讯，完美医疗(01830)发布公告，季志雄先生已辞任独立非执行董事、本公司薪酬委员会主席以及本公司审核委员会及提名委员会各自之成员，自2026年9月30日起生效，原因为彼希望投放更多时间于其他业务。独立非执行董事戚世昌先生已获委任为薪酬委员会主席，自2026年9月30日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01830","BK1215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208351","title":"复星医药(02196)：Wenjie Zhang辞任联席总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208351","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671208351?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:51","pubTimestamp":1790761912,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，2026年9月30日，公司董事会收到 Wenjie Zhang 先生的书面辞职函。因个人原因，Wenjie Zhang 先生向董事会辞去公司联席总裁职务，其辞任于送达董事会时生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK1515","BK0187","02196","BK1191","BK0012","BK0028","BK0175","BK0188","BK0239","BK0196","BK0183","BK0096","BK1593","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275129","title":"港股异动 | 三生制药(01530)涨超3% 旗下三生蔓迪携手德睿智药达成MDR-001独家合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275129","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671275129?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:50","pubTimestamp":1790751052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药涨超3%，截至发稿，涨3.54%，报32.74港元，成交额1543.68万港元。消息面上，据三生制药官微消息，9月28日，三生制药旗下子公司浙江三生蔓迪药业有限公司及万晟医药宣布，与杭州德睿智药科技有限公司就其自主研发的AI设计口服小分子GLP-1受体激动剂MDR-001，达成覆盖中国内地、中国香港及中国澳门的独家商业化合作。MDR-001目前正在中国开展针对成人肥胖或超重人群的Ⅲ期关键临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK4588","BK4585","HK0000165453.HKD","BK1161","BK1583","VXUS","KCAI","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224954","title":"股市必读：复星医药新发布《复星医药关于2025年A股股票期权激励计划预留授予结果公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224954?lang=zh_cn&edition=full","pubTime":"2026-09-30 01:16","pubTimestamp":1790702172,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，复星医药报收于23.39元，上涨0.65%，换手率1.37%，成交量29.06万手，成交额6.85亿元。公司公告汇总复星医药关于2025年A股股票期权激励计划预留授予结果公告上海复星医药（集团）股份有限公司已完成2025年A股股票期权激励计划的预留授予登记工作。本次预留授予登记日为2026年9月24日，实际授予A股期权合计723,300份，涉及激励对象共99人，行权价格为27.93元/股，股票来源为公司从二级市场回购的A股库存股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000001772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","399300","83130","03130","83188","600196","BK0028","159982","BK0012","BK1147","BK0239","BK1593","02823","BK0187","BK0196","82822","07233","02846","BK1191","02843","02827","82843","BK0188","BK1610","03188","82823","82846","BK0175","BK0096","BK0183","02822","BK1515","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671251705","title":"股市必读：复星医药新发布《复星医药H股公告-翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671251705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671251705?lang=zh_cn&edition=full","pubTime":"2026-09-29 01:12","pubTimestamp":1790615537,"startTime":"0","endTime":"0","summary":"公司公告汇总复星医药H股公告-翌日披露报表上海复星医药(集团)股份有限公司于2026年9月25日购回62,000股H股股份，每股购回价介乎17.34港元至17.47港元，总代价为1,080,535港元。该等股份拟持作库存股份。本次购回在联交所进行，占购回前已发行股份的0.01%。复星医药关于2025年A股股票期权激励计划预留授予结果公告上海复星医药（集团）股份有限公司已完成2025年A股股票期权激励计划的预留授予登记工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900001550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1593","BK0096","BK0183","02196","BK0060","BK0239","BK1515","BK0196","BK1191","BK0175","BK0187","600196","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235746","title":"三生制药(01530)9月28日斥资2041万港元回购130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235746","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670235746?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:03","pubTimestamp":1790589820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，该公司于2026年9月28日斥资2041万港元回购130万股股份，每股回购价格为15.6-15.8港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","HK0000165453.HKD","BK1583","BK1161","01530","HELS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670451400","title":"瑞丽至孟连高速公路项目建设进度条再刷新","url":"https://stock-news.laohu8.com/highlight/detail?id=2670451400","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670451400?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:47","pubTimestamp":1790560020,"startTime":"0","endTime":"0","summary":"近日，瑞孟高速公路项目建设传来新进展：朝阳1号隧道中导洞顺利进洞施工，正式进入实质性开挖阶段；盾中2号隧道左幅实现顺利贯通。新闻多一点瑞丽至孟连高速公路是云南省“十三五”期间高速公路建设重点项目之一。全长512.11公里，概算投资639.38亿元，按双向4车道高速公路标准建设。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-28/doc-initiwik2945116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","02135","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670240219","title":"复星医药于9月25日斥资108.05万港元回购6.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670240219","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670240219?lang=zh_cn&edition=full","pubTime":"2026-09-28 08:27","pubTimestamp":1790555220,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端复星医药（02196）发布公告，于2026年9月25日，该公司斥资108.05万港元回购6.2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-28/doc-initirzp9728819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0096","BK0028","BK0060","BK0196","BK0188","BK0183","BK0012","BK1515","02196","BK1191","BK1593","BK0175","BK0187","BK0239","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670381409","title":"股市必读：复星医药新发布《复星医药关于控股子公司签订合作与许可协议的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670381409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670381409?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:12","pubTimestamp":1790529134,"startTime":"0","endTime":"0","summary":"公司公告汇总：复星医药于9月24日及25日连续两日实施H股回购，合计购回134,000股，总代价约235万港元，均拟作库存股份。公司公告汇总复星医药关于控股子公司签订合作与许可协议的公告2026年9月23日，复星医药控股子公司复宏汉霖与Amberstone签订《合作与许可协议》，获得基于T-MATE技术平台针对两个靶点开发两款T细胞衔接器产品的全球独家许可。本次购回在联交所进行，占购回前已发行股份的0.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1191","BK0187","BK0175","BK0188","600196","BK0183","BK0028","BK0060","02196","BK0012","BK1593","BK0096","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669678064","title":"【投融资动态】新烛时代天使+融资，融资额数千万人民币，投资方为中金资本、天鹰资本等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669678064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669678064?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:23","pubTimestamp":1790248989,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于9月22日公布的信息整理，北京新烛时代科技有限公司天使+融资，融资额数千万人民币，参与投资的机构包括中金资本，天鹰资本，顺创产投，中新绿电。新烛时代成立于2025年9月，核心逻辑在于实现“AI for Fusion”，即利用AI作为智慧大脑，解决聚变反应中最棘手的难题。其产品主要聚焦于为聚变装置提供从观测诊断到实时控制的全链路解决方案。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400035394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06699","MUCmain","CYB","UCmain","BK1593","MCNHmain","BK1583","BK1100","BK1587","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669650274","title":"复星医药(02196)9月24日斥资126.95万港元回购7.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669650274","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669650274?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:17","pubTimestamp":1790241426,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月24日斥资126.95万港元回购7.2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0196","600196","BK0188","BK0096","BK0028","BK0183","BK1593","02196","BK0012","BK1191","BK0187","BK0239","BK1515","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548376","title":"三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548376","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669548376?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:02","pubTimestamp":1790164971,"startTime":"0","endTime":"0","summary":"三生官方资料将其列为益比奥、特比澳开发的领导科学家和主要研究员。2007年三生制药登陆纳斯达克，是国内较早赴美上市的生物药企之一。2015年三生回港上市，公司大事记称其当年成为全球生物制药领域受关注IPO之一。娄竞接手后先扩后收，早期保留赛普汀等肿瘤抗体，2020年前后逐步把资源收回到自身免疫。国健年报披露，相关款项三生国健占30%、沈阳三生占70%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790134731525398876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01530","BK0239","BK1583","HK0000165453.HKD","BK1593","BK1161","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669935109","title":"复星医药：复宏汉霖获Amberstone授予独家许可，协议包含至多2.36亿美元的总付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669935109","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669935109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:38","pubTimestamp":1790152732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HK0000165453.HKD","02196","HK0000320223.HKD","BK0188","BK1515","HK0000306685.HKD","BK1593","BK0012","BK0196","HK0000306701.USD","BK0183","BK1161","BK0187","BK0060","BK1191","600196","BK0239","BK0028","BK0096","02696","HK0000320264.USD","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669124624","title":"股市必读：XD昊海生物科技新发布《H股公告：翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669124624","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669124624?lang=zh_cn&edition=full","pubTime":"2026-09-23 03:26","pubTimestamp":1790105181,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，XD昊海生物科技报收于30.1元，上涨0.8%，换手率0.28%，成交量5468.0手，成交额1645.08万元。公司公告汇总H股公告：翌日披露报表上海昊海生物科技股份有限公司于2026年9月21日提交翌日披露报表，报告显示公司于当日购回27,500股H股，每股购回价介乎15.8至15.96港元，总代价为438,274港元。该等股份拟注销，不持有作库存股份。截至2026年9月21日，公司累计已根据授权购回926,300股H股，占授权时已发行股份的2.6633%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300004710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486721","title":"复星医药(02196.HK)9月22日斥资2179.16万港元回购120万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486721","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669486721?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:40","pubTimestamp":1790070038,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1191","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154902","title":"卓珈控股(01827.HK)：王千华获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154902","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154902?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:39","pubTimestamp":1789983546,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1215","BK1593","01827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154429","title":"复星医药：9月21日斥资486.23万港元回购27.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154429","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154429?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:35","pubTimestamp":1789983300,"startTime":"0","endTime":"0","summary":"南财智讯9月21日电，复星医药（02196.HK）发布翌日披露报表，公司于2026年9月21日在香港联交所进行股份回购，回购股份数量为271500股，每股最高回购价17.98港元，每股最低回购价17.78港元，付出的总代价为4862335港元。该等回购股份拟持作库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880099430.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880099430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1593","02196","BK0175","BK0239","BK0183","BK0028","600196","BK0196","BK0188","BK0012","BK1515","BK0096","BK0060","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}